Oncology
Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study
In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28%. Up to 80% of people with this type of HCC experience disease recurrence, at which point they are...
Hepatoblastoma
Hepatoblastoma is a very rare liver cancer (malignant tumor) that affects babies and toddlers ages 1 to 3. It’s treated with surgery. Rarely, hepatoblastoma may spread outside children’s livers. Hepatoblastoma may be “cured” with chemotherapy to shrink cancerous...
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis. The study is evaluating Tecentriq® (atezolizumab) in...
Webinar: “The PERIO-02 Trial – Enabling Immunotherapy for Intrahepatic Cholangiocarcinoma”
In this webinar, Steven C. Katz, M.D., FACS, Chief Medical Officer at TriSalus Life Sciences, leads a review of the Pressure-Enabled Regional Immuno-Oncology (PERIO-02) clinical trial for adults with intrahepatic cholangiocarcinoma and hepatocellular carcinoma, the...
Early Data from PERIO-01 Presented at Recent Society for Immunotherapy of Cancer (STIC) Workshop
Dr. Sapna Patel from MD Anderson presented early data from the Pressure-Enabled Regional Immuno-Oncology-01 (PERIO-01) clinical trial at SITC’s Tumor Microenvironment: A Holistic Approach Workshop. Early findings suggest Pressure-Enabled Drug Delivery™ enabled SD-101...
A Cure in Sight and the Ocular Melanoma Foundation Collaborate to Host Webinar on PERIO-01 Clinical Trial for Uveal Melanoma with Liver Metastases
A Cure in Sight, in collaboration with the Ocular Melanoma Foundation, hosted an educational webinar on the Pressure-Enabled Regional Immuno-Oncology-01 (PERIO-01) clinical trial for uveal melanoma with liver metastases. This webinar featured insights from Drs....
Achieving Health Equity in Liver Cancer
Primary liver cancer death rates vary by region, and much is still to be done in the area of health equity. Primary liver cancer is a leading cause of cancer-related illness and death worldwide. It is the sixth most-common cancer and the third most-common cause of...
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
Health related quality of life (HRQOL) for patients undergoing treatment for unresectable hepatocellular carcinoma is an important therapeutic consideration. The evidence of HRQOL benefits in clinically relevant domains support the use of lenvatinib compared with...
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma is a common cancer worldwide and a leading cause of cancer-related death. Although early-stage disease may be curable by resection, liver transplantation, or ablation, most patients present with unresectable disease and have a poor prognosis....
Pediatric Oncology
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.